Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 3 · below the Ichimoku cloud · RSI 31 · MACD above its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.3M | 0.00% | 179.60K | −13% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a QTTB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 24, 2026 | Violette Shelia MOfficer | Sale at price 16.56 per share. | 2.8K | $46.34K |
| Aug 24, 2026 | Kalowski LeePresident | Sale at price 16.56 per share. | 4K | $65.78K |
| Aug 24, 2026 | Morrison Jodie PopeChief Executive Officer | Sale at price 16.56 per share. | 9.8K | $163.03K |
| Jul 15, 2026 | Kalowski LeePresident | Stock Award(Grant) at price 0.00 per share. | 53.3K | — |
| Jul 15, 2026 | Morrison Jodie PopeChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 132K | — |
| Jul 15, 2026 | Violette Shelia MOfficer | Stock Award(Grant) at price 0.00 per share. | 37.5K | — |
| Jun 29, 2026 | Manke IsaacDirector | Conversion of Exercise of derivative security at price 2.80 per share. | 53.5K | $149.86K |
| May 27, 2026 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 10.31 per share. | 1.88M | $19.33M |
| May 27, 2026 | Xu DiyongDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 10.31 per share. | 1.88M | $19.33M |
| Feb 24, 2026 | Violette Shelia MOfficer | Sale at price 4.51 per share. | 2.8K | $12.71K |
| Feb 24, 2026 | Kalowski LeePresident | Sale at price 4.51 per share. | 4K | $18.04K |
| Feb 24, 2026 | Morrison Jodie PopeChief Executive Officer | Sale at price 4.51 per share. | 9.9K | $44.67K |
| Feb 23, 2026 | Kalowski LeePresident | Stock Award(Grant) at price 0.00 per share. | 53.3K | — |
| Feb 23, 2026 | Morrison Jodie PopeChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 132K | — |
| Feb 23, 2026 | Violette Shelia MOfficer | Stock Award(Grant) at price 0.00 per share. | 37.5K | — |
| Dec 1, 2025 | Kalowski LeePresident | Sale at price 3.46 per share. | 9.1K | $31.39K |
| Dec 1, 2025 | Morrison Jodie PopeChief Executive Officer | Sale at price 3.46 per share. | 22.5K | $77.87K |
| Aug 25, 2025 | Violette Shelia MOfficer | Sale at price 1.80 per share. | 3K | $5.38K |
| Aug 25, 2025 | Kalowski LeePresident | Sale at price 1.80 per share. | 4.2K | $7.64K |
| Aug 25, 2025 | Morrison Jodie PopeChief Executive Officer | Sale at price 1.80 per share. | 10.5K | $18.90K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.9 | 17.5 | 40.8 | -12.8 | 97.3 | 15.3 | 23.1 | -5.2 | -44.4 | -2.5 | +142.8% | ||
| 2025 | -11.9 | -25.1 | -27.3 | -3.0 | 8.1 | -13.9 | 49.0 | -23.0 | 15.8 | 41.9 | -22.1 | 51.6 | −3.5% |
| 2024 | 10.2 | 37.3 | 2.9 | 60.8 | -6.9 | -29.6 | 112.1 | 14.2 | 2.6 | 5.8 | -43.0 | -87.2 | −68.6% |
| 2023 | 24.6 | -3.2 | -32.2 | -7.8 | 2.8 | -9.4 | 57.1 | -13.7 | -2.5 | -11.1 | -48.9 | 14.5 | −51.7% |
| 2022 | 2.2 | -6.2 | -12.9 | -45.4 | -11.4 | 34.0 | 9.1 | 8.8 | -31.2 | -7.5 | 3.4 | -18.2 | −65.4% |
| 2021 | 7.6 | -11.6 | -12.4 | -28.1 | -1.9 | 9.5 | -12.5 | 13.1 | 9.5 | -27.2 | -11.9 | -27.9 | −67.8% |
| 2020 | -24.4 | 2.2 | -2.9 | -22.3 | 18.0 | 6.7 | -13.4 | -19.2 | 0.7 | -1.2 | -6.9 | 14.7 | −45.5% |
| 2019 | -9.3 | 45.4 | -5.9 | -22.4 | -5.9 | -3.3 | -9.1 | 6.4 | -4.3 | -27.5 | 21.9 | 29.4 | −7.4% |
| 2018 | 6.9 | 0.7 | 1.3 | -13.7 | -5.5 | 37.3 | -17.7 | 16.8 | 1.7 | +19.6% |
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Buy / hold / sell counts